Flibanserin Approval Seen as Positive Read-Thru for Sarepta Therapeutics (SRPT), Others - Roth Capital Aug 19, 2015 09:06AM
Sarepta Therapeutic (SRPT) NDA Submission Marks 'Significant De-risking Event', Roth Capital Says Jun 29, 2015 08:21AM
WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says May 21, 2015 11:25AM
Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth Capital May 20, 2015 06:23AM
Pre-Open Stock Movers 05/06: (GEVA) (BRDR) (FATE) (MGI) Higher; (WLT) (ZU) (NDLS) Lower (more...) May 6, 2015 09:27AM


Feb 9, 2010 07:26AM Roth Capital Upgrades BioMarin Pharmaceutical (BMRN) to Buy
Jan 7, 2010 10:54AM Notable Analyst Rating Changes 1/7: BAC, SHLD, THC, IT, ZUMZ, CITP Upgraded; RAI, AA, RAD, WEN, BEXP Downgraded
Oct 19, 2009 10:15AM Roth Capital Downgrades BioMarin Pharmaceuticals (BMRN) to Hold
Jul 2, 2008 09:50AM Notable Analyst Rating Changes 7/2: XOM, VSE, RAI, FITB Upgraded; DEO, PXP, UAUA Downgraded
Jul 2, 2008 08:30AM Roth Capital Starts BioMarin (BMRN) at Hold; $27 PT